Join
Live feed
·
PRReleasevia Quantisnow
CytomX Therapeutics Inc. logo

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CTMX· CytomX Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTMX (CytomX Therapeutics Inc.) and more on Quantisnow.